William A. Cochrane

Founded in 2006, Avrio Ventures Ltd (Avrio) is a venture capital firm founded in 2002 and headquarters in Calgary with additional offices located in Montreal and Toronto. The firm is also known as Avrio Capital.

QSV Biologics Ltd. manufactures biopharmaceutical products for pre-clinical research, phase I, II and III clinical trials materials. The private company is based in Edmonton, Canada. and has subsidiaries in Canada.

Fox Energy Corp. engages in exploration and production of oil and gas. The company is headquartered in Calgary, Canada.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Part of Sophiris Bio, Inc., Nucleus Bioscience, Inc. is a Canadian capital pool company. The company is based in Surrey, Canada. Nucleus Bioscience was acquired by Brightwave Ventures, Inc. on June 18, 2003.

Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada.

XS Technologies, Inc. is a Canadian development stage company.